Surmodics, Inc. (NASDAQ: SRDX) Stock Competitors & Peer Comparison
See SRDX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SRDX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRDX | $42.98 | +0.00% | 614.5M | -34.66 | -$1.24 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.95 | -0.03% | 174.7B | 19.37 | $5.21 | +2.46% |
| MDT | $87.09 | -2.69% | 111.5B | 15.75 | $5.53 | +3.28% |
| SYK | $278.77 | +1.26% | 106.9B | 20.83 | $13.39 | +1.25% |
| BSX | $43.88 | -0.52% | 65.2B | 14.15 | $3.10 | N/A |
| EW | $88.08 | +1.44% | 50.7B | 32.63 | $2.70 | N/A |
| DXCM | $86.64 | -0.05% | 32.7B | 33.98 | $2.55 | N/A |
| GEHC | $66.46 | -0.48% | 30B | 14.57 | $4.56 | +0.21% |
| PHG | $24.77 | -1.35% | 24.2B | 14.15 | $1.75 | +4.02% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
SRDX vs BSX-PA Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SRDX's ROE is -0.10%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
SRDX vs ABT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ABT trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABT's P/E ratio is 19.37. In terms of profitability, SRDX's ROE is -0.10%, compared to ABT's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ABT's competition here
Medtronic plc (NYSE: MDT)
SRDX vs MDT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDT has a market cap of 111.5B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while MDT trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDT's P/E ratio is 15.75. In terms of profitability, SRDX's ROE is -0.10%, compared to MDT's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
SRDX vs SYK Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SYK has a market cap of 106.9B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SYK trades at $278.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SYK's P/E ratio is 20.83. In terms of profitability, SRDX's ROE is -0.10%, compared to SYK's ROE of +0.16%. Regarding short-term risk, SRDX is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
SRDX vs BSX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX has a market cap of 65.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BSX trades at $43.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX's P/E ratio is 14.15. In terms of profitability, SRDX's ROE is -0.10%, compared to BSX's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
SRDX vs EW Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EW has a market cap of 50.7B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while EW trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EW's P/E ratio is 32.63. In terms of profitability, SRDX's ROE is -0.10%, compared to EW's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
SRDX vs DXCM Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while DXCM trades at $86.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DXCM's P/E ratio is 33.98. In terms of profitability, SRDX's ROE is -0.10%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, SRDX is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
SRDX vs GEHC Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while GEHC trades at $66.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GEHC's P/E ratio is 14.57. In terms of profitability, SRDX's ROE is -0.10%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
SRDX vs PHG Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PHG trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PHG's P/E ratio is 14.15. In terms of profitability, SRDX's ROE is -0.10%, compared to PHG's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
SRDX vs ZBH Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ZBH trades at $91.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZBH's P/E ratio is 10.77. In terms of profitability, SRDX's ROE is -0.10%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SRDX is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
SRDX vs ABMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SRDX's ROE is -0.10%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
SRDX vs SWAV Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SRDX's ROE is -0.10%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SRDX is less volatile compared to SWAV. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
SRDX vs PEN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PEN trades at $318.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PEN's P/E ratio is 83.26. In terms of profitability, SRDX's ROE is -0.10%, compared to PEN's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
SRDX vs SNN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SNN trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SNN's P/E ratio is 18.19. In terms of profitability, SRDX's ROE is -0.10%, compared to SNN's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
SRDX vs BIO-B Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, SRDX's ROE is -0.10%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, SRDX is similarly volatile compared to BIO-B. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
SRDX vs ALGN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ALGN has a market cap of 10.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ALGN trades at $144.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ALGN's P/E ratio is 13.13. In terms of profitability, SRDX's ROE is -0.10%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
SRDX vs BIO Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BIO trades at $379.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO's P/E ratio is 40.90. In terms of profitability, SRDX's ROE is -0.10%, compared to BIO's ROE of +0.03%. Regarding short-term risk, SRDX is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
SRDX vs GMED Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while GMED trades at $75.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GMED's P/E ratio is 17.06. In terms of profitability, SRDX's ROE is -0.10%, compared to GMED's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
SRDX vs BRKR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BRKR trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKR's P/E ratio is 32.42. In terms of profitability, SRDX's ROE is -0.10%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, SRDX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
SRDX vs BRKRP Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BRKRP trades at $470.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKRP's P/E ratio is 256.72. In terms of profitability, SRDX's ROE is -0.10%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, SRDX is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BRKRP's competition here
Masimo Corporation (NASDAQ: MASI)
SRDX vs MASI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MASI's P/E ratio is 44.43. In terms of profitability, SRDX's ROE is -0.10%, compared to MASI's ROE of +0.09%. Regarding short-term risk, SRDX is similarly volatile compared to MASI. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
SRDX vs GKOS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GKOS has a market cap of 9.4B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while GKOS trades at $158.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GKOS's P/E ratio is -184.34. In terms of profitability, SRDX's ROE is -0.10%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, SRDX is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
SRDX vs PODD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PODD trades at $132.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PODD's P/E ratio is 22.63. In terms of profitability, SRDX's ROE is -0.10%, compared to PODD's ROE of +0.27%. Regarding short-term risk, SRDX is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
SRDX vs HAE Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while HAE trades at $105.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas HAE's P/E ratio is 21.13. In terms of profitability, SRDX's ROE is -0.10%, compared to HAE's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
SRDX vs NARI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NARI's P/E ratio is -59.24. In terms of profitability, SRDX's ROE is -0.10%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to NARI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
SRDX vs ITGR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ITGR trades at $126.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ITGR's P/E ratio is 19.90. In terms of profitability, SRDX's ROE is -0.10%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, SRDX is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
SRDX vs LIVN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while LIVN trades at $76.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LIVN's P/E ratio is 18.29. In terms of profitability, SRDX's ROE is -0.10%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
SRDX vs IRTC Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while IRTC trades at $114.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRTC's P/E ratio is -265.63. In terms of profitability, SRDX's ROE is -0.10%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, SRDX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
SRDX vs AXNX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SRDX's ROE is -0.10%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SRDX is similarly volatile compared to AXNX. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
SRDX vs TMDX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while TMDX trades at $84.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TMDX's P/E ratio is 42.68. In terms of profitability, SRDX's ROE is -0.10%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, SRDX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
SRDX vs NEOG Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NEOG trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NEOG's P/E ratio is 45.46. In terms of profitability, SRDX's ROE is -0.10%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
SRDX vs BFLY Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BFLY trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BFLY's P/E ratio is -37.90. In terms of profitability, SRDX's ROE is -0.10%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, SRDX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
SRDX vs UFPT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while UFPT trades at $296.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas UFPT's P/E ratio is 30.33. In terms of profitability, SRDX's ROE is -0.10%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, SRDX is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
SRDX vs AXGN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AXGN trades at $42.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXGN's P/E ratio is 111.68. In terms of profitability, SRDX's ROE is -0.10%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, SRDX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
SRDX vs INSP Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while INSP trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INSP's P/E ratio is 32.26. In terms of profitability, SRDX's ROE is -0.10%, compared to INSP's ROE of +0.18%. Regarding short-term risk, SRDX is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check INSP's competition here
NuVasive, Inc. (NASDAQ: NUVA)
SRDX vs NUVA Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SRDX's ROE is -0.10%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
SRDX vs ESTA Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ESTA trades at $63.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ESTA's P/E ratio is -50.56. In terms of profitability, SRDX's ROE is -0.10%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, SRDX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
SRDX vs NVCR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NVCR trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NVCR's P/E ratio is -12.30. In terms of profitability, SRDX's ROE is -0.10%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, SRDX is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
SRDX vs ATEC Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ATEC trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ATEC's P/E ratio is -172.83. In terms of profitability, SRDX's ROE is -0.10%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, SRDX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
SRDX vs CNMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CNMD trades at $46.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CNMD's P/E ratio is 10.26. In terms of profitability, SRDX's ROE is -0.10%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, SRDX is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
SRDX vs HSKA Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SRDX's ROE is -0.10%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SRDX is similarly volatile compared to HSKA. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
SRDX vs IART Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while IART trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IART's P/E ratio is 7.05. In terms of profitability, SRDX's ROE is -0.10%, compared to IART's ROE of -0.01%. Regarding short-term risk, SRDX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
SRDX vs AVNS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVNS's P/E ratio is 27.77. In terms of profitability, SRDX's ROE is -0.10%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, SRDX is less volatile compared to AVNS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
SRDX vs TNDM Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while TNDM trades at $16.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TNDM's P/E ratio is -17.82. In terms of profitability, SRDX's ROE is -0.10%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, SRDX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
SRDX vs SILK Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SILK's P/E ratio is -18.96. In terms of profitability, SRDX's ROE is -0.10%, compared to SILK's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to SILK. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
SRDX vs AORT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AORT trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AORT's P/E ratio is 38.07. In terms of profitability, SRDX's ROE is -0.10%, compared to AORT's ROE of -0.01%. Regarding short-term risk, SRDX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
SRDX vs IRMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while IRMD trades at $86.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRMD's P/E ratio is 43.45. In terms of profitability, SRDX's ROE is -0.10%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, SRDX is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
SRDX vs FNA Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas FNA's P/E ratio is -19.83. In terms of profitability, SRDX's ROE is -0.10%, compared to FNA's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
SRDX vs ENOV Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ENOV trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ENOV's P/E ratio is 5.29. In terms of profitability, SRDX's ROE is -0.10%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, SRDX is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
SRDX vs PRCT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PRCT trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PRCT's P/E ratio is -9.39. In terms of profitability, SRDX's ROE is -0.10%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, SRDX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
SRDX vs LMRI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LMRI has a market cap of 985.8M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while LMRI trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LMRI's P/E ratio is -19.96. In terms of profitability, SRDX's ROE is -0.10%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, SRDX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
SRDX vs BVS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BVS has a market cap of 948.5M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BVS trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BVS's P/E ratio is 18.42. In terms of profitability, SRDX's ROE is -0.10%, compared to BVS's ROE of +0.28%. Regarding short-term risk, SRDX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
SRDX vs CBLL Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CBLL has a market cap of 943.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CBLL trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CBLL's P/E ratio is -14.12. In terms of profitability, SRDX's ROE is -0.10%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, SRDX is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
SRDX vs BBNX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BBNX has a market cap of 873.2M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BBNX trades at $19.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BBNX's P/E ratio is -11.76. In terms of profitability, SRDX's ROE is -0.10%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, SRDX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BBNX's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
SRDX vs SIBN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SIBN has a market cap of 849.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SIBN trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SIBN's P/E ratio is -56.32. In terms of profitability, SRDX's ROE is -0.10%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, SRDX is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
SRDX vs CSII Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CSII's P/E ratio is -20.83. In terms of profitability, SRDX's ROE is -0.10%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SRDX is less volatile compared to CSII. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
SRDX vs INMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INMD has a market cap of 817.4M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while INMD trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INMD's P/E ratio is 9.88. In terms of profitability, SRDX's ROE is -0.10%, compared to INMD's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
SRDX vs VREX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while VREX trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas VREX's P/E ratio is 19.44. In terms of profitability, SRDX's ROE is -0.10%, compared to VREX's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
SRDX vs AHCO Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AHCO has a market cap of 771.4M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AHCO trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AHCO's P/E ratio is 11.57. In terms of profitability, SRDX's ROE is -0.10%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, SRDX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check AHCO's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
SRDX vs CTKB Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CTKB has a market cap of 743.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CTKB trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CTKB's P/E ratio is -30.51. In terms of profitability, SRDX's ROE is -0.10%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, SRDX is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CTKB's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
SRDX vs AVR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVR has a market cap of 738M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while AVR trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVR's P/E ratio is -3.91. In terms of profitability, SRDX's ROE is -0.10%, compared to AVR's ROE of -0.78%. Regarding short-term risk, SRDX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check AVR's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
SRDX vs KIDS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, KIDS has a market cap of 584.6M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while KIDS trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas KIDS's P/E ratio is -19.29. In terms of profitability, SRDX's ROE is -0.10%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, SRDX is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
SRDX vs APEN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas APEN's P/E ratio is -9.43. In terms of profitability, SRDX's ROE is -0.10%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SRDX is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
SRDX vs SSII Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SSII's P/E ratio is -48.17. In terms of profitability, SRDX's ROE is -0.10%, compared to SSII's ROE of -0.27%. Regarding short-term risk, SRDX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SSII's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
SRDX vs PACB Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PACB has a market cap of 568.4M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PACB trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PACB's P/E ratio is -4.46. In terms of profitability, SRDX's ROE is -0.10%, compared to PACB's ROE of -49.62%. Regarding short-term risk, SRDX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PACB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
SRDX vs DCTH Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DCTH has a market cap of 547.2M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while DCTH trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DCTH's P/E ratio is 1585.00. In terms of profitability, SRDX's ROE is -0.10%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, SRDX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
SRDX vs ZIMV Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SRDX's ROE is -0.10%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, SRDX is similarly volatile compared to ZIMV. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check ZIMV's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
SRDX vs SGHT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SGHT has a market cap of 508.7M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SGHT trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SGHT's P/E ratio is -16.70. In terms of profitability, SRDX's ROE is -0.10%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, SRDX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
SRDX vs TCMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TCMD has a market cap of 508.2M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while TCMD trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TCMD's P/E ratio is 20.86. In terms of profitability, SRDX's ROE is -0.10%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
SRDX vs CERS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CERS has a market cap of 497.8M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CERS trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CERS's P/E ratio is -82.06. In terms of profitability, SRDX's ROE is -0.10%, compared to CERS's ROE of -0.10%. Regarding short-term risk, SRDX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
SRDX vs NPCE Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NPCE has a market cap of 475.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NPCE trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NPCE's P/E ratio is -24.46. In terms of profitability, SRDX's ROE is -0.10%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, SRDX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
SRDX vs SENS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SENS has a market cap of 420M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SENS trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SENS's P/E ratio is -4.51. In terms of profitability, SRDX's ROE is -0.10%, compared to SENS's ROE of -1.66%. Regarding short-term risk, SRDX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
SRDX vs OFIX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, OFIX has a market cap of 394.1M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while OFIX trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas OFIX's P/E ratio is -6.35. In terms of profitability, SRDX's ROE is -0.10%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, SRDX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
SRDX vs CLPT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CLPT has a market cap of 353M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CLPT trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CLPT's P/E ratio is -9.97. In terms of profitability, SRDX's ROE is -0.10%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, SRDX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CLPT's competition here
CapsoVision, Inc. (NASDAQ: CV)
SRDX vs CV Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CV has a market cap of 334.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CV trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CV's P/E ratio is -10.62. In terms of profitability, SRDX's ROE is -0.10%, compared to CV's ROE of -1.78%. Regarding short-term risk, SRDX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
SRDX vs SMLR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SRDX's ROE is -0.10%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, SRDX is similarly volatile compared to SMLR. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
SRDX vs TMCI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TMCI has a market cap of 299.7M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while TMCI trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TMCI's P/E ratio is -4.91. In terms of profitability, SRDX's ROE is -0.10%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, SRDX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
SRDX vs CATX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CATX has a market cap of 298.8M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while CATX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CATX's P/E ratio is -1.97. In terms of profitability, SRDX's ROE is -0.10%, compared to CATX's ROE of -0.42%. Regarding short-term risk, SRDX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check CATX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
SRDX vs RCEL Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RCEL has a market cap of 297.1M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while RCEL trades at $11.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RCEL's P/E ratio is -8.31. In terms of profitability, SRDX's ROE is -0.10%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, SRDX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
SRDX vs INFU Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INFU has a market cap of 263M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while INFU trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INFU's P/E ratio is 31.78. In terms of profitability, SRDX's ROE is -0.10%, compared to INFU's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check INFU's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
SRDX vs TLSI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TLSI has a market cap of 261.7M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while TLSI trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TLSI's P/E ratio is -2.53. In terms of profitability, SRDX's ROE is -0.10%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, SRDX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check TLSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
SRDX vs MGRM Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MGRM's P/E ratio is -12.00. In terms of profitability, SRDX's ROE is -0.10%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, SRDX is similarly volatile compared to MGRM. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
SRDX vs ELMD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ELMD has a market cap of 232.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ELMD trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ELMD's P/E ratio is 21.47. In terms of profitability, SRDX's ROE is -0.10%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, SRDX is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
SRDX vs NVRO Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SRDX's ROE is -0.10%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SRDX is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
SRDX vs PROF Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PROF has a market cap of 207.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while PROF trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PROF's P/E ratio is -5.84. In terms of profitability, SRDX's ROE is -0.10%, compared to PROF's ROE of -0.56%. Regarding short-term risk, SRDX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
SRDX vs RXST Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RXST has a market cap of 197.5M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while RXST trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RXST's P/E ratio is -4.22. In terms of profitability, SRDX's ROE is -0.10%, compared to RXST's ROE of -0.17%. Regarding short-term risk, SRDX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
SRDX vs BSGM Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SRDX's ROE is -0.10%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, SRDX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check BSGM's competition here
Quantum-Si incorporated (NASDAQ: QSI)
SRDX vs QSI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QSI has a market cap of 189.5M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while QSI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QSI's P/E ratio is -2.08. In terms of profitability, SRDX's ROE is -0.10%, compared to QSI's ROE of -0.47%. Regarding short-term risk, SRDX is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check QSI's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
SRDX vs MDGS Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SRDX's ROE is -0.10%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SRDX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check MDGS's competition here
Quanterix Corporation (NASDAQ: QTRX)
SRDX vs QTRX Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QTRX has a market cap of 172.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while QTRX trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QTRX's P/E ratio is -1.44. In terms of profitability, SRDX's ROE is -0.10%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, SRDX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
SRDX vs FOCL Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, FOCL has a market cap of 170.2M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while FOCL trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas FOCL's P/E ratio is -4.39. In terms of profitability, SRDX's ROE is -0.10%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, SRDX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
SRDX vs STIM Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, STIM has a market cap of 164.2M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while STIM trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas STIM's P/E ratio is -5.36. In terms of profitability, SRDX's ROE is -0.10%, compared to STIM's ROE of -1.51%. Regarding short-term risk, SRDX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
SRDX vs QIPT Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QIPT's P/E ratio is -15.87. In terms of profitability, SRDX's ROE is -0.10%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SRDX is similarly volatile compared to QIPT. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
SRDX vs LUCD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LUCD has a market cap of 154.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while LUCD trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LUCD's P/E ratio is -2.19. In terms of profitability, SRDX's ROE is -0.10%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, SRDX is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
SRDX vs INGN Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INGN has a market cap of 145.4M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while INGN trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INGN's P/E ratio is -5.90. In terms of profitability, SRDX's ROE is -0.10%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
SRDX vs ICAD Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ICAD's P/E ratio is -20.37. In terms of profitability, SRDX's ROE is -0.10%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, SRDX is similarly volatile compared to ICAD. This indicates similar risk in terms of short-term price fluctuations for SRDX.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
SRDX vs HJLI Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas HJLI's P/E ratio is N/A. In terms of profitability, SRDX's ROE is -0.10%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, SRDX is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check HJLI's competition here
electroCore, Inc. (NASDAQ: ECOR)
SRDX vs ECOR Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ECOR has a market cap of 98.1M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ECOR trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ECOR's P/E ratio is -6.48. In terms of profitability, SRDX's ROE is -0.10%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, SRDX is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ECOR's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
SRDX vs ASXC Comparison September 2026
Surmodics, Inc. (NASDAQ: SRDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, SRDX is priced at $42.98 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ASXC's P/E ratio is -1.12. In terms of profitability, SRDX's ROE is -0.10%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, SRDX is less volatile compared to ASXC. This indicates lower risk in terms of short-term price fluctuations for SRDX.Check ASXC's competition here